Xenon Pharmaceuticals Inc.
XENE
$58.81
-$0.74-1.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -- | -- | -- |
| Cost of Revenue | 39.53% | 44.38% | 43.04% | 42.04% | 42.00% |
| Gross Profit | -43.80% | -49.31% | -39.47% | -38.13% | -37.78% |
| SG&A Expenses | 22.07% | 15.40% | 15.57% | 18.97% | 22.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.61% | 37.33% | 36.26% | 36.30% | 37.09% |
| Operating Income | -38.81% | -40.84% | -33.57% | -33.37% | -33.93% |
| Income Before Tax | -45.49% | -50.73% | -44.66% | -44.83% | -41.76% |
| Income Tax Expenses | 55.55% | 51.35% | 124.85% | -655.61% | -1,443.11% |
| Earnings from Continuing Operations | -47.07% | -52.38% | -47.62% | -43.56% | -39.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.07% | -52.38% | -47.62% | -43.56% | -39.77% |
| EBIT | -38.81% | -40.84% | -33.57% | -33.37% | -33.93% |
| EBITDA | -39.21% | -41.27% | -33.89% | -33.79% | -34.99% |
| EPS Basic | -33.88% | -46.28% | -44.99% | -38.30% | -29.45% |
| Normalized Basic EPS | -32.36% | -44.63% | -42.10% | -39.42% | -30.82% |
| EPS Diluted | -33.88% | -46.28% | -44.99% | -38.30% | -29.45% |
| Normalized Diluted EPS | -32.36% | -44.63% | -42.10% | -39.42% | -30.82% |
| Average Basic Shares Outstanding | 10.31% | 4.16% | 1.74% | 4.00% | 7.80% |
| Average Diluted Shares Outstanding | 10.31% | 4.16% | 1.74% | 4.00% | 7.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |